ABOUT
About Mycenax
Management Team
Milestone
PRESS CENTER
News
Events
Videos
INSIGHT
CDMO SERVICES
Druggability
Cell Line Development
Process Development
Analytical Methods
PIC/S GMP Production
Plasmid DNA
Antibody-Drug Conjugates
Cell and Gene Therapy
Exosomes
CAREERS
Join Us
Career Development
Welfare and Events
ESG
ESG
Corporate Governance
Stakeholders
Community Involvement
INVESTOR RELATIONS
Financial Information
Information of Shareholders
Major Shareholders
Investor Contact Information
SUPPORT
Contact
Sitemap
Privacy
Languages
Languages
繁中
English
PRESS CENTER
新聞中心
PRESS CENTER
News
2022/05/30
Mycenax re-elected Dr. Allen Y. Chao as independent director
返回列表
BACK
相關消息
related news
2021/08/26
Mycenax Reports 2022 H1 EPS of NT$0.32 with business expansion from traditional biologics to allogeneic cell therapy and emerging biologics.
2022/09/21
Mycenax signs MoU with KriSan Biotech: Building ADC Industry Value Chain
2022/07/28
JCR Pharmaceuticals invests in Mycenax Biotech, becomes largest shareholder
2021/05/28
Mycenax becomes Taiwan’s first CDMO company to complete the CHO-S and CHOZN® GS Cell Line Development with the Beacon® Optofluidic System
GO TOP
This website uses cookies to ensure you get the best experience on our website.
我們在網站上使用cookies以改善網站的功能和使用，並用於分析和廣告目的。如果您繼續使用本網站而未變更您的cookies設置，則表示您同意我們使用cookies。
I agree.
我同意
